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Abstract
The molecular basis to mammalian osteoarthritis (OA) is
unknown. We hypothesised that the expression of selected
proteases, matrix molecules, and collagens believed to have a
role in the pathogenesis of OA would be changed in naturally
occurring canine OA cartilage when compared to normal
articular cartilage. Quantitative (real-time) reverse transcriptase-
polymerase chain reaction assays were designed measuring the
expression of selected matrix molecules (collagens and small
leucine-rich proteoglycans), key mediators of the proteolytic
degradation of articular cartilage (metalloproteinases,
cathepsins), and their inhibitors (tissue inhibitors of matrix
metalloproteinases). All data were normalised using a geometric
mean of three housekeeping genes, and the results subjected to
power calculations and corrections for multiple hypothesis
testing. We detected increases in the expression of BGN,
COL1A2, COL2A1, COL3A1, COL5A1, CSPG2, CTSB,
CTSD, LUM, MMP13, TIMP1, and TNC in naturally occurring
canine OA. The expression of TIMP2 and TIMP4 was
significantly reduced in canine OA cartilage. The patterns of
gene expression change observed in naturally occurring canine
OA were similar to those reported in naturally occurring human
OA and experimental canine OA. We conclude that the
expression profiles of matrix-associated molecules in end-stage
mammalian OA may be comparable but that the precise
aetiologies of OA affecting specific joints in different species are
presently unknown.
Introduction
Osteoarthritis (OA) is the most common debilitating disease of
mammalian joints. The clinical prevalence of human OA has
been estimated to affect 12.1% of the population aged 25 to
74 [1], whereas clinical OA affects up to 20% of the canine
population at large [2]. Canine OA usually develops secondary
to an identifiable initiating cause (for example, secondary to hip
dysplasia [3]), although it can be experimentally induced [4].
Experimental models provide controlled and reproducible
development of OA [5], but only the study of naturally occur-
ring disease allows experimental findings to be directly related
to the clinical presentation with absolute certainty. The related-
ness of the pathogenesis of a common disease, such as OA,
in two different species has not been characterised [6].
At present, the precise mechanisms underlying the molecular
pathogenesis of OA are unknown. Quantification of gene
expression is a fundamental tool for investigating gene func-
tion in biological systems, particularly for elucidating patholog-
ical mechanisms at play in diseased tissues. Quantitative
reverse transcriptase-polymerase chain reaction (RT-PCR) is
currently considered the most accurate technique for quantify-
ing gene expression. With the publication of the canine
genome [7], RT-PCR assays can now be readily designed forPage 1 of 9
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specific oligonucleotide microarrays are available for the quan-
tification of mRNA transcripts in canine tissue, such as carti-
lage [8], quantitative RT-PCR validation of the results
produced is still required.
Articular cartilage is composed of chondrocytes embedded in
an extracellular matrix (ECM). The structural strength of the
matrix is provided by collagens such as type II collagen
(COL2), type VI collagen (COL6), type IX collagen (COL9),
type XI collagen (COL11), and type XVI collagen (COL16),
with COL2 accounting for 90% to 95% of the collagen com-
position of the ECM. Other than water, the major non-colla-
genous component of articular cartilage is aggrecan (AGC1);
smaller components include the small leucine-rich proteogly-
cans such as biglycan (BGN), chondroitin sulphate proteogly-
can 2 (CSPG2), decorin (DCN), lumican (LUM), and tenascin
C (TNC). The proteolytic degradation of normal and osteoar-
thritic cartilage matrix is performed by proteases such as the
matrix metalloproteinases (MMPs) [9], members of the
ADAMTS (a disintegrin and metalloproteinase with throm-
bospondin-like motif) family (or 'aggrecanases') [10], and lys-
osomal proteases (such as cathepsins) [11]. Tissue inhibitors
of matrix metalloproteinases (TIMPs) are naturally occurring
inhibitors of MMP and ADAMTS function [12]. The authors
are unaware of any publications documenting the change in
expression of structural ECM and protease collagens in the
articular cartilage of dogs with naturally occurring OA. We
hypothesised that the expression of selected proteases, matrix
molecules, and collagens would be modulated in naturally
occurring canine OA.
Materials and methods
Cartilage samples
Osteoarthritic articular cartilage was harvested from the femo-
ral heads of dogs that had end-stage naturally occurring OA
secondary to hip dysplasia (n = 15, mean age 2.7 years [range
1 to 12 years], mean weight 28.2 kg [range 25 to 36 kg]) and
that were undergoing routine surgical treatment of the disease
(total hip replacement). In all cases, severe clinical and radio-
graphic signs associated with OA of the affected joint neces-
sitated surgical treatment of the disease. Articular cartilage
was harvested from the area surrounding the central cartilage
erosion usually observed on the canine OA hip [3]. Normal
articular cartilage was harvested without visual evidence of hip
dysplasia or OA from the femoral heads of dogs, which had
been euthanatised for reasons unrelated to joint disease (n =
13, mean age 3.3 years [range 1 to 11 years], mean weight
26.2 kg [range 15 to 40 kg]). Articular cartilage was obtained
from the same site of the femoral head in the control dogs as
it was in diseased dogs. Cartilage samples were immediately
immersed in RNAlater™ (Ambion Ltd., Huntingdon, UK) at
room temperature for 24 hours before being stored at -20°C
until use, in accordance with the manufacturer's instructions.
RNA extraction from articular cartilage
Tissue samples were removed from RNAlater™ and total RNA
was extracted using phenol/guanidine HCl reagents (Trizol™;
Invitrogen Ltd, Paisley, UK) and isolated as previously
described [13,14]. An on-column DNA digestion step was
included (RNase-Free DNase Set; Qiagen Ltd, Crawley, UK).
Final elution of the total RNA was performed using 30 μl of
RNase-free water and repeated to maximise the amount of
RNA eluted.
RNA quality assessment
The concentration of total RNA of each sample was quantified
by using a spectrophotometer (NanoDrop Technologies,
Wilmington, DE, USA). RNA integrity was analysed by evalu-
ating the capillary electrophoresis trace (Agilent 2100 Bioan-
alyser; Agilent Technologies, Santa Clara, CA, USA) of the
sample by using the RNA integrity number (RIN) algorithm
[15], degradation factor (DF) [16], and ribosomal peak ratio.
The sample was determined to have minimal or no loss of
integrity (RIN >6.4 and/or DF <10 and/or a ribosomal ratio
>0.4) and thus deemed suitable for use in the following exper-
iments in accordance with a previously developed quality algo-
rithm [14].
Synthesis of cDNA
Each sample was normalised to a concentration of 20 μg/μl,
using RNAse-free water, and reverse transcription was per-
formed using 10 μl RNA (200 μg total RNA) with oligo-dT12–
18 and Superscript II reverse transcriptase (Invitrogen Ltd).
After reverse transcription, the template was diluted with 500
μl RNase/DNase-free water. cDNA was stored at -80°C until
later use in quantitative PCR.
Quantitative PCR
Transcript sequences were obtained from the canine genome
database [17], with cross-reference to the National Center for
Biotechnology Information (Bethesda, MD, USA) [18]. Where
possible, assays were designed in areas of sequence showing
100% homology between predicted and verified sequences.
Primer and probe sequences were designed using online
design software [19]. To enhance the probability of transcript-
specific PCR, selected amplicon systems were designed so
that the last six to seven bases of a 3' primer or the probe
crossed an exon-exon boundary. When this was not possible,
the primers were designed to be hybridised on different exons,
with an intronic sequence greater than 1,100 base pairs, to
maintain specificity for mRNA. Some assays could be
designed within only a single exon, and thus a genomic DNA
assay was also designed to determine whether genomic con-
tamination was present. BLAST (Basic Local Alignment
Search Tool) searches were performed for all primer
sequences to confirm gene specificity.
Genes were selected for assay on the basis of their impor-
tance to cartilage homeostasis or pathology as derived from aPage 2 of 9
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mental canine OA and from the results of a preliminary canine-
specific whole genome microarray study, using a small number
of samples. Assays were designed for quantification of expres-
sion of five collagen genes (type I collagen, alpha 2 chain
[COL1A2], type II collagen alpha 1 chain [COL2A1], type III
collagen alpha 1 chain [COL3A1], type V collagen alpha 1
chain [COL5A1], and type IX collagen alpha 3 chain
[COL9A3]), six ECM genes (AGC1, BGN, CSPG2, DCN,
LUM, and TNC), an intermediate filament (vimentin), proteases
and their inhibitors (ADAMTS-5, cathepsins B [CTSB], cathe-
psin D [CTSD], MMP13, TIMP1, TIMP2, and TIMP4), and
genomic DNA. Assays for four reference genes (glyceralde-
hyde-3-phosphate dehydrogenase [GAPDH], TATA box bind-
ing protein [TBP], ribosomal protein L13a [RPL13A], and
succinate dehydrogenase complex, subunit A [SDHA]) (Table
1) were also designed. The reference genes used were
selected from a panel of reference genes by applying a gene
stability algorithm [20]. Primers were synthesised by MWG
Biotech (London, UK). Locked nucleic acid fluorescence res-
onance energy transfer probes with a 5' reporter dye FAM (6-
carboxy fluorescein) anda dark quencher dyewere synthesised
by Roche Diagnostics Ltd (Lewes, West Sussex, UK).
The quantitative (real-time) PCR assays were all performed in
triplicate using a TaqMan™ ABI PRISM 7900 SDS (Applied
Biosystems, Foster City, CA, USA) in 384-well plate format.
Each assay well had a 10-μl reaction volume consisting of 5 μl
Table 1
A list of primer and probe sequences for the genes evaluated
Gene Forward Reverse Probe
ADAMTS5 TGGGTTCCCAAATATGCAG CTGTCCCATCCGTCACCT CTGGGAGA
1AGC1 GGGACCTGTGTGAGATCGAC GTAACAGTGGCCCTGGAACT AGGAGCTG
BGN CAGAACAACGACATCTCAGAGC TCACCAGGACGAGAGCGTA CTCCACCA
COL1A2 CTATCAATGGTGGTACCCAGTTT TGTTTTGAGAGGCATGGTTG GCCTGCTG
COL2A1 CTGGTGAACCTGGACGAGAG ACCACGATCACCCTTGACTC CCTCCTGG
COL3A1 GGATGGTGGCTTCCAGTTT CCAGCTGGACATCGAGGA GCTGCCTG
COL5A1 AACCTGTCGGATGGCAAGT CAGTCCAAGATCAAGGTGACAT CAGCATCC
COL9A3 CGAGGTGCCTCAGGTGAC ACCCAGCTCTCCTTTGTCC GAGACCAG
CSPG2 TGGATGGTTTTAATACGTTCAGG GCCGTAGTCACACGTCTCTG CTGCCTTC
CTSB CGGCCTTCACCGTGTACT GTGACGTGCTGGTACACTCC CTTCCTGC
CTSD GGTCCACATGGAGCAGGT TATGAGGGAGGTGCCTGTGT TGGGCAGC
DCN CGCTGTCAGTGCCATCTC GGGGGAAGATCTTTTGGTACTT TCCAGTGT
GAPDH CTGGGGCTCACTTGAAAGG CAAACATGGGGGCATCAG CTGCTCCT
Genomic AACCCTCAAAGATGAGGTTTAGC ACTCTGGGATCACGCATGT CTGCCTTC
LUM ACCTGGAAATTCTTTTAATGTATCATC CGGTATGTTTTTAAGCTTATTGTAGGA TGCTGGAG
MMP13 CCGCGACCTTATCTTCATCT AACCTTCCAGAATGTCATAACCA AGAGGCAG
RPL13A CTGCCCCACAAGACCAAG GGGATCCCATCAAACACCT CCAGGCTG
SDHA GGTGGCACTTCTACGACACC ATGTAGTGGATGGCGTCCTG CTGGCTGG
TBP TCCACAGCCTATCCAGAACA CTGCTGCTGTTGTCTCTGCT CTGGAGGA
TIMP1 TGCATCCTGCTGTTGCTG AACTTGGCCCTGATGACG CCCAGCAG
TIMP2 ATGGGCTGTGAGTGCAAGAT CACTCATCCGGAGACGAGAT CTGCCCCA
TIMP4 GCAGAGAGAAAGTCTGAATCATCA GGCACTGTATAGCAGGTGGTAA TGTGGCTG
TNC TGGATGGGACAGTCAAGGA GCTCAGCTCTGCCAGGTTA CCACCTCC
VIM TACAGGAAGCTGCTGGAAGG CCTCAGGTTCAGGGAAGAAA GAGCAGGA
ADAMTS5, ADAM metallopeptidase with thrombospondin type 1 motif, 5; AGC1, aggrecan; BGN, biglycan; COL1A2, type I collagen, alpha two 
chain; COL2A1, type II collagen alpha 1 chain; COL3A1, type III collagen alpha 1 chain; COL5A1, type V collagen alpha 1 chain; COL9A3, type 
IX collagen alpha 3 chain; CSPG2, chondroitin sulphate proteoglycan 2; CTSB, cathepsin B; CTSD, cathepsin D; DCN, decorin; GAPDH, 
glyceraldehyde-3-phosphate dehydrogenase; Genomic, Genomic DNA, LUM, lumican;MMP13, matrix metalloproteinase 13; RPL13A, ribosomal 
protein L13a; SDHA, succinate dehydrogenase complex, subunit A; TBP, TATA box binding protein; TIMP1, tissue inhibitor of metalloproteinase 
1; TIMP2, tissue inhibitor of metalloproteinase 2; TIMP4, tissue inhibitor of metalloproteinase 4; TNC, Tenascin C; VIM, vimentin.Page 3 of 9
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Mastermix; Applied Biosystems), 0.1 μl each of 20 μM forward
and reverse primers, 0.1 μl of 10 μM probe (Exiqon; Roche
Diagnostics Ltd), and 4.7 μl of sample cDNA (templates) or
water (negative controls).
The amplification was performed according to standard proto-
col with 10 minutes at 50°C followed by 40 cycles of 95°C for
1 minute and 60°C for 15 seconds, as recommended by the
manufacturer (Applied Biosystems). Real-time data were ana-
lysed by using the Sequence Detection Systems software,
version 2.2.1 (Applied Biosystems). The detection threshold
was set manually at 0.05 for all assays. Standard curves were
generated for each assay (Additional file 1), to confirm that all
assays were generated within acceptable limits (efficiency
93% > x > 107.4%) and R2 values (R2 > 0.98) (with the excep-
tion of the genomic contamination assay, in which efficiency
was lower, but the detection of any transcript was deemed
unacceptable).
Data analysis
The weights and ages of the patients were normally distributed
and thus compared with the calculation of means and Student t
tests. The weight of the articular cartilage samples and quantity of
RNA extract were compared using median values and Mann-
Whitney U tests because the data were not normally distributed.
Table 2
The dynamic range, standard curve slope, R2 value, and efficiency of each polymerase chain reaction assay
Assay Lower detection limit (CT value) Upper detection limit (CT value) Standard curve slope R2 value Efficiency
ADAMTS5 26.0 35.9 -3.32 0.99 100.2
AGC 18.5 34.7 -3.29 0.99 101.5
BGN 20.8 34.8 -3.49 1.00 93.3
COL1A2 17.4 33.5 -3.30 1.00 101.0
COL2A1 22.7 32.2 -3.22 1.00 104.6
COL3A1 16.5 33.0 -3.33 1.00 99.9
COL5A1 23.2 33.1 -3.31 1.00 100.5
COL9A3 26.3 32.7 -3.22 1.00 104.8
CSPG2 21.4 34.3 -3.25 1.00 103.2
CTSB 19.7 32.6 -3.24 1.00 103.3
CTSD 24.1 34.2 -3.29 1.00 101.5
DCN 19.0 31.9 -3.25 1.00 103.0
GAPDH 22.7 35.2 -3.27 0.99 102.3
Genomic 16.8 40.0 -4.42 1.00 68.3
LUM 19.9 33.7 -3.48 1.00 93.9
MMP13 26.1 36.3 -3.36 0.98 98.6
RPL13A 18.6 32.1 -3.36 1.00 98.6
SDHA 21.6 34.6 -3.26 1.00 102.5
TBP 16.5 30.0 -3.39 1.00 97.4
TIMP1 22.6 33.1 -3.48 1.00 93.7
TIMP2 21.8 32.1 -3.43 1.00 95.7
TIMP4 29.5 35.8 -3.16 0.99 107.4
TNC 20.1 33.0 -3.26 1.00 102.5
VIM 15.8 32.7 -3.35 1.00 98.8
See Additional file 1 for further details. ADAMTS5, ADAM metallopeptidase with thrombospondin type 1 motif, 5; AGC1, aggrecan; BGN, 
biglycan; COL1A2, type I collagen, alpha two chain; COL2A1, type II collagen alpha 1 chain; COL3A1, type III collagen alpha 1 chain; COL5A1, 
type V collagen alpha 1 chain; COL9A3, type IX collagen alpha 3 chain; CSPG2, chondroitin sulphate proteoglycan 2; CTSB, cathepsin B; 
CTSD, cathepsin D; DCN, decorin; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; LUM, lumican;MMP13, matrix metalloproteinase 13; 
RPL13A, ribosomal protein L13a; SDHA, succinate dehydrogenase complex, subunit A; TBP, TATA box binding protein; TIMP1, tissue inhibitor 
of metalloproteinase 1; TIMP2, tissue inhibitor of metalloproteinase 2; TIMP4, tissue inhibitor of metalloproteinase 4; TNC, Tenascin C; VIM, 
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cycle (CT) values from each transcript in triplicate. Geometric
means [20] were calculated for the combined three reference
genes (GAPDH, TBP, and RPL13A) and used to calculate the
ΔΔCT (delta-delta CT) values and the relative amount of each
target gene [21] (Table 2). A fourth reference gene (SDHA)
was not included as a reference gene, because it was found
to have differential expression between normal and OA sam-
ples, even when included as part of the normalisation calcula-
tion. The upper detection limit of dynamic range generated
from the standard curves was used as a cut-off point, above
which real-time data were discarded (that is, included in the
statistical analyses as zero/no transcript present).
Data were compared with the calculations of means, standard
deviations, and fold changes from normal and paired two-
tailed t tests (body weight and age) performed in a spread-
sheet program (Microsoft Excel 2003; Microsoft Corporation,
Redmond, WA, USA) and the calculation of graphs, 95% con-
fidence intervals (CIs) of the mean, and Mann-Whitney U tests
(to compare the amount of each target) performed in a statis-
tical analysis software package (Minitab version 14.1; Minitab
Ltd., Coventry, UK). One-sided power calculations were per-
formed, assuming normality from the two samples with une-
qual variance and using a freely available web-based program
[22]. Significance was established at p < 0.05, and a robust
statistical analysis was assumed to have a power value greater
than or equal to 80%. Data were checked for errors due to
Table 3
Change in gene expression, mean 2-ΔΔCT values, significance and power of comparisons between normal and OA canine articular 
cartilage
Gene Number of samples in which expression was 
detected
2-ΔΔCT normal 2-ΔΔCT OA Fold change in expression 
(diseased versus normal)
Mann-Whitney U 
test p value
Power
TIMP4 27 0.109 0.043 -0.608 0.0094 0.859
TIMP2 28 3.959 1.664 -0.580 0.0020 0.844
ADAMTS5 16 0.031 0.019 -0.551 0.8478 0.175
SDHA 28 0.323 0.234 -0.275 0.0476 0.722
VIM 28 32.742 28.909 -0.117 0.5493 0.195
TBP 28 0.106 0.106 0.001 0.8178 0.051
DCN 28 73.034 74.253 0.017 0.5190 0.059
GAPDH 28 1.548 1.648 0.064 0.9633 0.105
RPL13A 28 7.048 7.722 0.096 0.3814 0.275
CTSB 26 0.280 0.476 0.698 0.0060 0.886
AGC 28 0.082 0.155 0.887 0.1670 0.778
TNC 28 2.700 5.205 0.927 0.0099 0.886
BGN 28 15.511 30.984 0.998 0.0043 0.976
CTSD 28 0.148 0.295 0.999 0.0066 0.944
COL9A3 27 0.231 0.546 1.365 0.0304 0.633
TIMP1 28 0.551 1.468 1.663 0.0008 0.853
LUM 28 1.635 4.476 1.738 0.0015 0.991
CSPG2 27 0.079 0.279 2.530 0.0005 0.981
COL5A1 28 0.615 2.188 2.555 0.0069 0.887
COL3A1 26 10.573 37.867 2.581 0.0011 0.982
COL1A2 28 0.805 6.941 7.621 0.0043 0.737
MMP13 26 0.014 0.161 10.322 0.0010 0.857
COL2A1 27 1.412 23.583 15.705 0.0001 0.779
ADAMTS5, ADAM metallopeptidase with thrombospondin type 1 motif, 5; AGC, aggrecan; BGN, biglycan; COL1A2, type I collagen, alpha two 
chain; COL2A1, type II collagen alpha 1 chain; COL3A1, type III collagen alpha 1 chain; COL5A1, type V collagen alpha 1 chain; COL9A3, type 
IX collagen alpha 3 chain; CSPG2, chondroitin sulphate proteoglycan 2; CTSB, cathepsin B; CTSD, cathepsin D; DCN, decorin; GAPDH, 
glyceraldehyde-3-phosphate dehydrogenase; LUM, lumican; MMP13, matrix metalloproteinase 13; OA, osteoarthritis; RPL13A, ribosomal protein 
L13a; SDHA, succinate dehydrogenase complex, subunit A; TBP, TATA box binding protein; TIMP1, tissue inhibitor of metalloproteinase 1; 
TIMP2, tissue inhibitor of metalloproteinase 2; TIMP4, tissue inhibitor of metalloproteinase 4; TNC, Tenascin C; VIM, vimentin.Page 5 of 9
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berg false discovery rate (FDR) [23].
Results
There were no significant differences between the ages (mean
control 3.3 years [± 3.2 years, range 1 to 12 years], mean OA
2.7 years [± 3.1 years, range 1 to 11 years], p = 0.768) or
body weights (mean control 26.2 kg [± 8.0 kg, range 15 to 32
kg], mean OA 28.3 kg [± 3.8 kg, range 23 to 36 kg], p =
0.109) of the dogs in the diseased and control groups. There
was no significant difference between the weight of the carti-
lage samples (median control 103 mg [range 45 to 260 mg],
median OA 92 mg [range 40 to 192 mg], p = 0.817) or the
quantity of RNA extracted, as determined by spectrophotome-
ter (median control 35 ng/μl [range 26 to 339 ng/μl], median
OA 42 ng/μl [range 22 to 247 ng/μl], p = 0.788).
Expression values are presented in Table 3. Two genes were
determined to have significant downregulation (TIMP2 and
TIMP4) in canine OA cartilage. One gene was determined to
be significantly downregulated (SDHA) but with a low power
value (72%); this gene was excluded after FDR correction.
Ten genes were determined to be significantly upregulated in
the OA samples (BGN, COL3A1, COL5A1, CSPG2, CTSB,
CSTD, LUM, MMP13, TIMP1, and TNC). Furthermore, in OA,
three genes were determined to be upregulated (COL1A2,
COL2A1, and COL9A3) but with low power values (74%,
78%, and 63%, respectively) and one gene was excluded
after FDR correction (COL9A3).
No amplification of genomic DNA was observed for any of the
samples. The average standard deviation for the triplicates in
each assay was 16.9% (range 7.3% to 37.9%), indicating that
all assays were reproducible. Eleven of the 2,592 data points
were removed because they were assumed to be aberrant
(markedly different from the other two values in the triplicate).
None of the 'no template' control wells (n = 864) revealed a
signal. Fold gene expression changes are illustrated in Figures
1 and 2, with all data normalised to the mean of the control val-
ues (with a fold change of 0 being no change, a fold change
of 1 meaning a doubling of expression, and a fold change of -
0.5 meaning a halving of expression). Statistical and power
calculations are reported in Table 3.
Figure 1
Graph illustrating the means and 95% confidence intervals (CIs) of the gene expression profiles. To normalise values, the mean of each control 
group has been used to normalise and produce fold changes in expression. The results of the COL9A3 transcript are omitted because the 95% CIs 
were very high. *Significant difference. ADAMTS5, ADAM metallopeptidase with thrombospondin type 1 motif, 5; AGC, aggrecan; COL9A3, type IX 
collagen alpha 3 chain; CTSB, cathepsin B; D, disease; DCN, decorin; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; N, normal; RPL13A, 
ribosomal protein L13a; SDHA, succinate dehydrogenase complex, subunit A; TBP, TATA box binding protein; TIMP2, tissue inhibitor of metallopro-
teinase 2; TIMP4, tissue inhibitor of metalloproteinase 4; TNC, Tenascin C; VIM, vimentin.Page 6 of 9
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Quantitative (real-time) RT-PCR is the most sensitive tech-
nique for the determination of mRNA transcript number [24].
To maximise the precision of our data, we included only mRNA
samples that had been determined as being of high quality
(using an algorithm determined by previous work [15]),
because mRNA degradation can affect assay performance
[24]. Assays were optimised within specific limits of efficiency,
and the dynamic range of each assay was determined, used,
and presented with the expression data. Additionally, we cor-
rected our results for multiple hypothesis testing (reducing the
opportunity for making a statistical type II error) and present
power values, allowing an interpretation of the strength of
each significant up- or downregulation.
If variables such as the methods of mRNA extraction, RNA
quality assessment, reverse transcription, assay design, meas-
urement of genomic contamination, standard curve data gen-
eration, reference gene selection, and data normalisation were
presented in the 'Materials and methods' and 'Results' sec-
tions of manuscripts using quantitative PCR, more appropriate
comparison of results between different studies could be
made. The geometric mean of three reference (housekeeping)
genes was used in this study to reduce the variability associ-
ated with the use of a single reference gene. Geometric mean
methodology has been validated as a more accurate normali-
sation technique than that using a single reference gene if the
reference genes are selected through the use of a stability
algorithm [21], although in this study one of the genes identi-
fied by the algorithm (SDHA) was not stably expressed (Table
3).
Gene expression varies with both the site of cartilage harvest
[25] and the degree of cartilage degeneration [26] in the OA
joint. We attempted to minimise this variability by using end-
stage OA, age- and weight-matched samples, and stringent
RNA quality control. A relatively high degree of heterogeneity
(large 95% CIs) was observed in the level of gene expression
measured from the clinical samples in this study, even existing
between samples within the same group. This may reflect dif-
ferences in dog age and/or breeds or variation in the time from
surgical removal to collection in the preservative fluid. The
analysis of additional samples or the phenotyping and selec-
tion of samples through histological grading may have
increased the statistical powers of each of these differences
observed, as the severity of OA measured by histology
(Mankin score) correlates with a reduction in the expression of
COL2 and AGC [27].
Cell culture-based biological systems provide a more control-
led methodology for evaluating gene expression when com-
pared with in vivo tissue. For example, increased cell numbers
can be obtained, breed and age factors can be eradicated,
and the absence of ECM facilitates the extraction of higher
quality of mRNA [16]. This is particularly true for studies of
smaller mammals such as the dog, in which clinical samples of
osteoarthritic cartilage may be less than 100 mg in size. How-
ever, cell-based models may differ in both gene expression
Figure 2
Graph illustrating the means and 95% confidence intervals (CIs) of the gene expression profiles. To normalise values, the mean of each control 
group has been used to normalise and produce fold changes in expression. The results of the COL9A3 transcript are omitted because the 95% CIs 
were very high. *Significant difference. BGN, biglycan; COL1A2, type I collagen, alpha two chain; COL2A1, type II collagen alpha 1 chain; 
COL3A1, type III collagen alpha 1 chain; COL5A1, type V collagen alpha 1 chain; COL9A3, type IX collagen alpha 3 chain; CSPG2, chondroitin 
sulphate proteoglycan 2; CTSD, cathepsin D; D, disease; LUM, lumican; MMP13, matrix metalloproteinase 13; N, normal; TIMP1, tissue inhibitor of 
metalloproteinase 1.Page 7 of 9
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mately, our understanding of the molecular pathogenesis of
OA requires relating changes observed with in vitro experi-
mentation to those identified from clinical tissue.
The paucity of literature reporting changes in gene expression
observed in naturally occurring canine OA implies that often
this is not easy to achieve. In part, this reflects the difficulties
associated with the use of clinical tissue samples, as noted
above, and the fact that the technology required to enable the
economic evaluation of gene expression across large groups
of tissue samples is only just becoming available. Indeed, we
were limited by sample quantity, quality, and cost and needed
to rationalise our list of genes selected for evaluation, as dis-
cussed previously.
We document marked elevation of expression in genes encod-
ing for collagen synthesis in the articular cartilage of dogs with
end-stage OA, which concurs with the findings in early exper-
imental canine OA [30-33]. COL1A2, COL3A1, and
COL5A1 are characteristically synthesised by cells with a
fibrocartilaginous phenotype [34].
The increased expression of BGN, CSPG2, CTSB, DCN,
LUM, MMP13, and TNC is consistent with previous studies of
expression of these genes in both naturally occurring human
[35-39] and experimental canine OA [30-32]. The biological
significance of fold changes in gene expression between con-
trol and OA samples is unknown in the absence of additional
data such as gross, radiographic, or histological scoring or
protein quantification. Likewise, the changes in gene expres-
sion documented do not specify whether these changes are
causal or simply associated with the development of pathology
in the OA joint.
We documented decreases in the expression of TIMP2 and
TIMP4 and an increase in the expression of TIMP1 in canine
OA cartilage. The decrease in TIMP4 expression was consist-
ent with expression profiles of human OA cartilage [39],
although TIMP1 expression has been documented as being
decreased and TIMP2 expression has been documented as
being unchanged in human OA [39]. Direct comparison of
gene expression levels with those measured in other joints
and/or in different species may be of limited value because the
underlying aetiologies to the development of OA may differ.
However, the evaluation of structural matrix components and
proteases affecting those components is still of interest
because the end-stage pathology characterising canine OA
mimics that described for human OA [40].
Conclusion
On the basis of the results we present, the gene expression of
selected matrix molecules and key mediators of the proteolytic
degradation of articular cartilage is changed in end-stage, nat-
urally occurring OA of the canine hip. The patterns of gene
expression change are broadly similar to those reported in
experimental canine stifle OA and naturally occurring human
OA.
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